Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
How Retatrutide Compares to Existing Therapies The progression from single to dual to triple agonist therapy represents a clear trend in obesity pharmacotherapy: Semaglutide (GLP-1 agonist): ~1517% weight loss in Phase III (STEP trials) Tirzepatide (GIP + GLP-1 dual agonist): ~2022.5% weight loss in Phase III (SURMOUNT trials) Retatrutide (GIP + GLP-1 + glucagon triple agonist): ~2629% weight loss in Phase III (TRIUMPH-4) Each additional receptor pathway appears to contribute incremental efficacy
)
I also love that they send me reminders for the appointment
Months three through twelve This is where the Virta Health data becomes your benchmark
.png)
Top tips for managing GLP-1 agonist side effects We recommend the following to help you manage the side effects listed above
)
US$ 28.54
US$ 27.21
US$ 20.55
US$ 27.55
